Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer

Pedro Nazareth Aguiar, Carmélia Maria Noia Barreto, Bárbara de Souza Gutierres, Hakaru Tadokoro, Gilberto de Lima Lopes

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE: To assess the cost-effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer.

METHODS: An analytical decision model was developed to determine the cost-effectiveness of chemohormonal therapy versus androgen deprivation therapy alone in patients with metastatic hormone-sensitive prostate cancer and patients with non-metastatic high-risk prostate cancer. The cost-effectiveness in metastatic patients with a high-volume disease was assessed separately. The model used data from randomized clinical trials and drug acquisition costs in Brazil. In addition, the costs of post-progression therapies have been included in this model. The benefits to health are expressed as the quality-adjusted life-years, and the incremental cost-effectiveness ratios were calculated.

RESULTS: Chemohormonal therapy may be associated with improved quality-adjusted life-years for all patient. The improvement was more than six times greater for patients with high-volume metastatic disease. In these patients, the incremental cost-effectiveness ratios were up to 74% lower than the incremental cost-effectiveness ratios of patients with non-metastatic disease.

CONCLUSION: Chemohormonal therapy has been more cost-effective in patients with high-volume metastatic disease.

Original languageEnglish (US)
Pages (from-to)349-354
Number of pages6
JournalEinstein (Sao Paulo, Brazil)
Volume15
Issue number3
DOIs
StatePublished - Jul 1 2017

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer'. Together they form a unique fingerprint.

Cite this